5604 results
Refine Your Search
"Who We Are" Article node
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
"Ways to Help" Article
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
"Advocate" article
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
"Research" Article
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
"News" Article
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
"Chemotherapy Drug Listing" Article
Lorem ipsum odor amet, consectetuer adipiscing elit. Nec dignissim sem; parturient dui tortor litora convallis. Sociosqu curabitur auctor aliquet susc…
Solu Therapeutics
Solu Therapeutics is a biotechnology company dedicated to developing therapeutics to eliminate cells in cancer, immunology and other therapeutic are…
A phase 1 study of STX-0712, a CCR2-CyTAC monocyte depletor, in patients with CMML
In December , LLS made an equity investment in Solu Therapeutics to "Support Preclinical and Clinical Development of in hematological malignancies, p…
Translating molecular profiles into treatment approaches to target disparities in lymphoma
Although many patients with diffuse large lymphoma (DLBCL) are cured with standard therapy, others will die from their disease. Survival is significa…
Research: Grants
Understanding Leukemia in Children with Down Syndrome to Develop Better Therapies
This Specialized Center of Research is focused on identifying the contributions of chromosome , which is present in three copies in individuals with D…
Paolo Caimi
Paolo Caimi is a physician and clinical investigator at the Cleveland Clinic, where he is also the Associate Bone Marrow Transplant Director for Cellu…
BAFF-ligand CAR T-cells and pre-apheresis B-cell lymphodepletion for relapsed/refractory CLL
Most CLL patients treated with CAR that target the CD19 antigen on the cell do not achieve a complete remission. CLL cells express other molecules on…
Research: Grants
Epigenetic Mechanisms and Targeting in Hematological Malignancy
Blood cancers can be caused by aberrant regulation of genes that control cell growth and development. The root cause of this problem may be the presen…
Genomic and epigenomic interactions of complex structural variants affecting outcome in multiple myeloma
Multiple myeloma is characterized by severe changes in chromosomes that result in gains or losses of genetic material. Several key events disrupt the …
Modeling LSC heterogeneity at unprecedented resolution in AML
Our goal is to perform molecular characterization of human leukemia stem cells (LSCs). We have developed an integrated set of techniques that will a…
Targeting Microenvironment Determinants in Peripheral T-cell Lymphoma
Peripheral lymphomas are highly aggressive blood cancer that have very poor survival rate, highlighting the need for new therapies to improve patient…
Teresa Palomero
Dr. Teresa Palomero is a molecular and cellular biologist. She is a Professor at Columbia University in the Institute for Cancer Genetics. Her laborat…
Interrogating T-cell apoptotic priming to improve CAR-T persistence in treatment of lymphoid malignancies
cells are made from a patient’s own immune cells, altered so that they specifically recognize and kill the patient’s cancer cells. They are effective …